Travere Therapeutics (TVTX)

• Market cap: $5.14B
• 1 day: -2.63%
• 5 days: -4.74%
• 1 month: 3.5%
• 3 months: 39.73%
• 6 months: 98.24%
• Year to date: 39.8%
• 1 year: 231.63%
• 5 years: 300.94%
• 10 years: 213.92%
• Sector: Healthcare
• Industry: Biotechnology

About: Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Employees: 497